DOCSLIB.ORG

Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-Cell Progenitors Are Affected by the ETV6–RUNX1 Rearrangement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-Cell Progenitors Are Affected by the ETV6–RUNX1 Rearrangement Published OnlineFirst July 24, 2014; DOI: 10.1158/1541-7786.MCR-14-0056-T Molecular Cancer Genomics Research Cytoskeletal Regulatory Gene Expression and Migratory Properties of B-cell Progenitors Are Affected by the ETV6–RUNX1 Rearrangement Chiara Palmi1, Grazia Fazio1, Angela M. Savino1, Julia Procter2, Louise Howell3, Valeria Cazzaniga1, Margherita Vieri1, Giulia Longinotti1, Ilaria Brunati1, Valentina Andre1, Pamela Della Mina4, Antonello Villa4, Mel Greaves2, Andrea Biondi1, Giovanna D'Amico1, Anthony Ford2, and Giovanni Cazzaniga1 Abstract Although the ETV6–RUNX1 fusion is a frequent initiating event in childhood leukemia, its role in leukemogenesis is only partly understood. The main impact of the fusion itself is to generate and sustain a clone of clinically silent preleukemic B-cell progenitors (BCP). Additional oncogenic hits, occurring even several years later, are required for overt disease. The understanding of the features and interactions of ETV6–RUNX1–positive cells during this "latency" period may explain how these silent cells can persist and whether they could be prone to additional genetic changes. In this study, two in vitro murine models were used to investigate whether ETV6– RUNX1 alters the cellular adhesion and migration properties of BCP. ETV6–RUNX1–expressing cells showed a significant defect in the chemotactic response to CXCL12, caused by a block in CXCR4 signaling, as demonstrated by inhibition of CXCL12-associated calcium flux and lack of ERK phosphorylation. Moreover, the induction of ETV6–RUNX1 caused changes in the expression of cell-surface adhesion molecules. The expression of genes regulating the cytoskeleton was also affected, resulting in a block of CDC42 signaling. The abnormalities described here could alter the interaction of ETV6–RUNX1 preleukemic BCP with the microenvironment and contribute to the pathogenesis of the disease. Implications: Alterations in the expression of cytoskeletal regulatory genes and migration properties of BCP represent early events in the evolution of the disease, from the preleukemic phase to the clinical onset, and suggest new strategies for effective eradication of leukemia. Mol Cancer Res; 12(12); 1796–806. Ó2014 AACR. Introduction normal cord blood (5), monozygotic twins (6), and animal – ETV6–RUNX1, generated by the t(12;21) chromosome modeling (7 13) indicate that this oncogene induces a preleukemic phenotype which is insufficient for overt leu- translocation, is the most common fusion gene in childhood – cancer, selectively associated with B-cell precursor acute kemogenesis. Indeed, ETV6 RUNX1 fusion generated lymphoblastic leukemia (BCP-ALL; refs. 1–3). The t during fetal hemopoiesis produces a clinically covert pre- (12;21) translocation fuses the protein dimerization domain leukemic clone that can persist postnatally for at least 15 years (4). Additional genetic abnormalities observed at of ETV6 with essentially all of the DNA binding and – – activating regions of RUNX1, generating an aberrant tran- diagnosis of ETV6 RUNX1 positive ALL are generally scription factor (2, 4). Observations on clinical samples, considered to be secondary events associated with the tran- sition of silent preleukemic cells to overt ALL (4). The understanding of which cellular signaling pathways 1Centro Ricerca Tettamanti, Clinica Pediatrica, Universita di Milano- are corrupted by ETV6–RUNX1 to sustain this persistent Bicocca, Monza, Italy. 2Centre for Evolution and Cancer, Division of Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey, preleukemic state might help to explain the vulnerability United Kingdom. 3Haemato-Oncology Research Unit, Division of Molec- of its constituent stem cells to secondary genetic changes. ular Pathology, The Institute of Cancer Research, Sutton, Surrey, United We have previously shown evidence that ETV6–RUNX1 Kingdom. 4Microscopy and Image Analysis Consortium, Universitadi b Milano-Bicocca, Monza, Italy. compromised the TGF signaling pathway, providing a plausible basis for both the persistence and maintenance of Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/). covert preleukemic clones in patients and their competitive positive selection in an inflammatory context (12). We and Corresponding Author: Andrea Biondi, Clinica Pediatrica, Universitadi Milano Bicocca, Ospedale San Gerardo, Via Pergolesi 33, Monza 20900, other investigators have also described an increased level of Italy. Phone: 39-0-392333661; Fax: 39-0-392332167; E-mail: heat shock proteins, survivin, has-mir-125b-2, and eryth- [email protected] ropoietin receptor in ETV6–RUNX1–positive cells, factors doi: 10.1158/1541-7786.MCR-14-0056-T that could provide the survival advantage to the preleukemic Ó2014 American Association for Cancer Research. clone (14–17). 1796 Mol Cancer Res; 12(12) December 2014 Downloaded from mcr.aacrjournals.org on October 2, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst July 24, 2014; DOI: 10.1158/1541-7786.MCR-14-0056-T ETV6–RUNX1 Inhibits CXCL12-Driven Cell Migration However, in addition to proliferative advantage and resis- the bicistronic retroviral vectors pMSCV-IRES-GFP (MIGR– tance to apoptotic signals, the site of localization and GFP) or pMSCV-ETV6-RUNX1-IRES-GFP, which allows interaction with the microenvironment is crucial to sustain the expression of ETV6–RUNX1 cDNA fused to c-Myc the hematopoietic stem cells in quiescence and the survival of epitope tag and GFP (MIGR–ETV6–RUNX1), as previously both normal and preleukemic cells (18). Moreover, altera- described (27). At day þ3 from transduction, cell sorting for tions in adhesive and chemotactic responses to normal GFP fluorescence was performed by the FACS Aria instrument stimuli have been described in BCR-ABL1–positive chronic (BD Biosciences). myeloid leukemia (19–21). The pre-BI cells were cultured on OP9 bone marrow Interestingly, some genes involved in cellular adhesion and stroma cells in Iscove modified Dulbecco medium (IMDM) cytoskeleton organization are listed among the RUNX1 supplemented with 2% FCS, 0.03% w/v primatone, and target genes (22–23), and changes in the expression of genes 100 units/mL IL7 (27). belonging to this functional pathway are described in ETV6–RUNX1–positive ALL (24–26). Antibodies and flow cytometry The aim of this work was to investigate whether the Phycoerythrin-conjugated antibodies anti-CD18 (M18/ ETV6–RUNX1 preleukemic clone showed alterations in 2), anti-CD11a (M17/4), anti-CD54 (YN1/1.7.4), anti- its adhesive and migratory properties that could provide a CD135 (A2F10), anti-CD29 (HMb 1-1), anti-CD49d rationale for its persistence and proliferation. (R1-2), anti-CD49e (HMa 5-1; e-Bioscience Inc.), and The preleukemic phase is usually clinically silent, whereas anti-CXCR7 (8F11-M16; Biolegend) were used. Allophy- the ETV6–RUNX1 leukemic clone at ALL diagnosis carries cocyanin-conjugated antibodies anti-CD44 (IM7) and anti- additional genetic abnormalities (4); for these reasons, we CXCR4 (2B11; e-Bioscience Inc.) were used. Data were used 2 alternative murine experimental systems: the Ba/F3 analyzed using CellQuest Software (BD Biosciences). pro-B cell line transduced with a hormone-inducible ETV6– RUNX1 (12) and pre-BI primary cells from fetal liver (27, Quantitative PCR array and real-time PCR 28) stably transduced with the pMIGR1–ETV6–RUNX1– The RT2 Profiler Assay Cytoskeleton Regulators PCR IRES–GFP construct. Array (SuperArray Bioscience) was performed following the In both model systems, we found evidence that ETV6– manufacturer's recommendation. RUNX1 alters the expression of cytoskeletal regulatory Real-time analysis was done on a Light Cycler 480II with genes, resulting in a block of the CDC42 signaling Universal Probe Master System (Roche Diagnostics; F. pathway, and compromises the chemotactic response to Hoffmann-La Roche Ltd.). Optimal primers and probe for CXCL12. amplification were selected by the Roche ProbeFinder soft- ware (https://www.roche-appliedscience.com/sis/rtpcr/upl). ÀDD Data were expressed using the comparative 2 Ct meth- Materials and Methods od (30), with the Hprt gene as a reference; for each gene Cell culture and ETV6–RUNX1 expression studied, the transcript level was always referred to that of The GeneSwitch System (Life Technologies), a mifepris- control cells. A fold change of <0.75 or >1.5 was considered tone-regulated expression system for mammalian cells, was as threshold for down- or upregulation, respectively. used to produce inducible expression of the ETV6–RUNX1 gene in the IL3-dependent murine pro-B cell line Ba/F3, as Adhesion assays previously described (12). Briefly, cells were transfected with Plates (96-well) were coated with fibronectin, murine the pSwitch plasmid (Invitrogen) expressing a GAL4 regu- stroma cell line OP9 (kindly provided by Prof. A. Rolink, latory fusion protein (control cells). Positive clones were then University of Basel), murine fresh stroma, or murine endo- transfected with pGene plasmid (Life Technologies) con- thelial cell lines 1G11 and MELC2 (a gift of Prof. A. Vecchi, taining the ETV6–RUNX1 cDNA fused to V5 epitope tag Instituto Clinico Humanitas, Rozzano, Italy). Details of the controlled by a promoter regulated by the GAL4 regulatory coating procedures: 50 mL fibronectin (Sigma-Aldrich), at a fusion protein (inducible ETV6-RUNX1 cells). All Ba/F3 concentration of 25 ng/mL in each of the 96 wells, was allow cells were cultured in RPMI supplemented with
Load more

Recommended publications
  • Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development
    International Journal of Molecular Sciences Review Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer and Development Charles Ducker * and Peter E. Shaw * Queen’s Medical Centre, School of Life Sciences, University of Nottingham, Nottingham NG7 2UH, UK * Correspondence: [email protected] (C.D.); [email protected] (P.E.S.) Abstract: Genome expansion, whole genome and gene duplication events during metazoan evolution produced an extensive family of ETS genes whose members express transcription factors with a conserved winged helix-turn-helix DNA-binding domain. Unravelling their biological roles has proved challenging with functional redundancy manifest in overlapping expression patterns, a common consensus DNA-binding motif and responsiveness to mitogen-activated protein kinase signalling. Key determinants of the cellular repertoire of ETS proteins are their stability and turnover, controlled largely by the actions of selective E3 ubiquitin ligases and deubiquitinases. Here we discuss the known relationships between ETS proteins and enzymes that determine their ubiquitin status, their integration with other developmental signal transduction pathways and how suppression of ETS protein ubiquitination contributes to the malignant cell phenotype in multiple cancers. Keywords: E3 ligase complex; deubiquitinase; gene fusions; mitogens; phosphorylation; DNA damage 1. Introduction Citation: Ducker, C.; Shaw, P.E. Cell growth, proliferation and differentiation are complex, concerted processes that Ubiquitin-Mediated Control of ETS Transcription Factors: Roles in Cancer rely on careful regulation of gene expression. Control over gene expression is maintained and Development. Int. J. Mol. Sci. through signalling pathways that respond to external cellular stimuli, such as growth 2021, 22, 5119. https://doi.org/ factors, cytokines and chemokines, that invoke expression profiles commensurate with 10.3390/ijms22105119 diverse cellular outcomes.
    [Show full text]
  • Hsa-Mir-125B-2 Is Highly Expressed in Childhood ETV6&Sol;RUNX1
    Leukemia (2010) 24, 89–96 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 N Gefen1,2,8, V Binder1,3,8, M Zaliova4, Y Linka3, M Morrow6, A Novosel3, L Edry5, L Hertzberg1,2,7, N Shomron5, O Williams6, J Trka4, A Borkhardt3 and S Izraeli1,2 1Section of Functional Genomics and Leukemia Research, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel-Hashomer, Israel; 2Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 3Department of Pediatric Hematology, Oncology and Immunology, Heinrich Heine University, Duesseldorf, Germany; 4Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Childhood Leukemia Investigation Prague, Prague, Czech Republic; 5Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 6Institute of Child Health, University College London, London, UK and 7Department of Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel MicroRNAs (miRNAs) regulate the expression of multiple characterized by an intrachromosomal amplification of a small proteins in a dose-dependent manner. We hypothesized that region within the long arm of chr 21 (iAMP21) around the increased expression of miRNAs encoded on chromosome 21 4 (chr 21) contribute to the leukemogenic function of trisomy 21. RUNX1 locus. In contrast to ETV6/RUNX1 and HHD ALL, it is The levels of chr 21 miRNAs were quantified by qRT–PCR in associated with poor prognosis.
    [Show full text]
  • HDAC3: Taking the SMRT-N-Correct Road to Repression
    Oncogene (2007) 26, 5439–5449 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW HDAC3: taking the SMRT-N-CoRrect road to repression P Karagianni and J Wong1 Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA Known histone deacetylases (HDACs) are divided into repression when targeted to promoters, as well as different classes, and HDAC3 belongs to Class I. Through physical association with the DNA-binding factor forming multiprotein complexes with the corepressors YY1 (Yang et al., 1997; Dangond et al., 1998; Emiliani SMRT and N-CoR, HDAC3 regulates the transcription et al., 1998). Together, these findings suggested that this of a plethora of genes. A growing list of nonhistone ubiquitously expressed protein could be involved in the substrates extends the role of HDAC3 beyond transcrip- regulation of mammalian gene expression. On the other tional repression. Here, we review data on the composi- hand, HDAC3 contains an intriguingly variable C tion, regulation and mechanism of action of the SMRT/ terminus, with no apparent similarity with other N-CoR-HDAC3 complexes and provide several examples HDACs. This observation led to the hypothesis that of nontranscriptional functions, to illustrate the wide HDAC3 may have some unique properties and may variety of physiological processes affected by this deacety- not be completely redundant with the other HDACs lase. Furthermore, we discuss the implication of HDAC3 (Yang et al., 1997). This is also suggested by the in cancer, focusing on leukemia. We conclude with some differential localization of HDAC3, which, unlike the thoughts about the potential therapeutic efficacies of predominantly nuclear HDACs 1 and 2, can be found in HDAC3 activity modulation.
    [Show full text]
  • The Complex Genetic Landscape of Familial MDS and AML Reveals Pathogenic Germline Variants
    ARTICLE https://doi.org/10.1038/s41467-020-14829-5 OPEN The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants Ana Rio-Machin et al.# The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we report a cohort of 86 acute myeloid leukemia (AML) and 1234567890():,; myelodysplastic syndrome (MDS) families with 49 harboring germline variants in 16 pre- viously defined loci (57%). Whole exome sequencing in a further 37 uncharacterized families (43%) allowed us to rationalize 65 new candidate loci, including genes mutated in rare hematological syndromes (ADA, GP6, IL17RA, PRF1 and SEC23B), reported in prior MDS/AML or inherited bone marrow failure series (DNAH9, NAPRT1 and SH2B3) or variants at novel loci (DHX34) that appear specific to inherited forms of myeloid malignancies. Altogether, our series of MDS/AML families offer novel insights into the etiology of myeloid malignancies and provide a framework to prioritize variants for inclusion into routine diagnostics and patient management. #A full list of authors and their affiliations appears at the end of the paper. NATURE COMMUNICATIONS | (2020) 11:1044 | https://doi.org/10.1038/s41467-020-14829-5 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-14829-5 nherited forms of myeloid malignancies are thought to be rare, Results Ialthough the precise
    [Show full text]
  • An Integrative Approach Reveals Genetic Complexity and Epigenetic
    Human Pathology (2019) 91,1–10 www.elsevier.com/locate/humpath Original contribution An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience☆ Nina Rahimi MD a,YanmingZhangMDb, Alain Mina MD c, Jessica K. Altman MD c, Madina Sukhanova PhD a, Olga Frankfurt MD c, Lawrence Jennings MD, PhD a, Xinyan Lu MD a,AmirBehdadMDa, Qing Chen MD, PhD a, Yi-Hua Chen MD a, Juehua Gao MD, PhD a,⁎ aDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA bDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA cDepartment of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA Received 10 March 2019; revised 8 May 2019; accepted 8 May 2019 Keywords: Summary Acute promyelocytic leukemia (APL) is a distinct type of acute myeloid leukemia that is Acute promyelocytic defined by the presence of the translocations that mostly involve the RARA gene. The most frequent leukemia; translocation is the t(15;17), which fuses the RARA gene with the PML gene. Previous studies have Next-generation shown that other cooperative mutations are required for the development of APL after the initiating sequencing; event of the t(15;17). In this study, we combined cytogenetics with next-generation sequencing and Somatic mutations; single-nucleotide polymorphism array to study the genetic complexity in 20 APL cases diagnosed in our in- SNP array; stitution. All but 3 cases had additional genetic aberrations. Our study demonstrated that somatic mutations Copy neutral loss of are frequent events in APL.
    [Show full text]
  • Immunohistochemical Expression of Wilms' Tumor 1 Protein In
    applied sciences Review Immunohistochemical Expression of Wilms’ Tumor 1 Protein in Human Tissues: From Ontogenesis to Neoplastic Tissues Lucia Salvatorelli 1,*, Giovanna Calabrese 2 , Rosalba Parenti 2 , Giada Maria Vecchio 1, Lidia Puzzo 1, Rosario Caltabiano 1 , Giuseppe Musumeci 3 and Gaetano Magro 1 1 Department of Medical and Surgical Sciences and Advanced Technologies, G.F. Ingrassia, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, Anatomic Pathology Section, School of Medicine, University of Catania, 95123 Catania, Italy; [email protected] (G.M.V.); [email protected] (L.P.); [email protected] (R.C.); [email protected] (G.M.) 2 Department of Biomedical and Biotechnological Sciences, Physiology Section, University of Catania, 95123 Catania, Italy; [email protected] (G.C.); [email protected] (R.P.) 3 Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, 95123 Catania, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-095-3702138; Fax: +39-095-3782023 Received: 4 October 2019; Accepted: 10 December 2019; Published: 19 December 2019 Abstract: The human Wilms’ tumor gene (WT1) was originally isolated in a Wilms’ tumor of the kidney as a tumor suppressor gene. Numerous isoforms of WT1, by combination of alternative translational start sites, alternative RNA splicing and RNA editing, have been well documented. During human ontogenesis, according to the antibodies used, anti-C or N-terminus WT1 protein, nuclear expression can be frequently obtained in numerous tissues, including metanephric and mesonephric glomeruli, and mesothelial and sub-mesothelial cells, while cytoplasmic staining is usually found in developing smooth and skeletal cells, myocardium, glial cells, neuroblasts, adrenal cortical cells and the endothelial cells of blood vessels.
    [Show full text]
  • Germline Mutations in Etv6 Result in Autosomal Dominant
    GERMLINE MUTATIONS IN ETV6 RESULT IN AUTOSOMAL DOMINANT THROMBOCYTOPENIA By LEILA J. NOETZLI B.S., University of California San Diego, 2007 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Human Medical Genetics and Genomics Program 2017 This thesis for the Doctor of Philosophy degree by Leila J. Noetzli has been approved for the Human Medical Genetics and Genomics Program by Robert Sclafani, Chair Jorge Di Paola, Advisor Jay Hesselberth Richard Spritz Rytis Prekeris Date: May 19, 2017 ii Noetzli, Leila J. (Ph.D., Human Medical Genetics and Genomics) Germline mutations in ETV6 result in autosomal dominant thrombocytopenia Thesis directed by Associate Professor Jorge Di Paola ABSTRACT Whole exome sequencing on a family with autosomal dominant thrombocytopenia and two occurrences of acute lymphoblastic leukemia (ALL) of unknown cause identified a heterozygous single nucleotide change in the gene ETV6, encoding a p.Pro214Leu amino acid substitution. We screened families with the same phenotype and found mutations in ETV6 in two additional families: one with the identical p.Pro214Leu mutation and one with a p.Arg418Gly substitution. ETV6 is a transcriptional repressor that functions through self-oligomerization and is essential for hematopoietic stem cell proliferation and platelet production in mice. Our report was among the first to describe pathogenic germline mutations in ETV6. Functional characterization of the corresponding ETV6 protein mutations showed aberrant cytoplasmic localization, impaired transcriptional repression, and delayed megakaryocyte maturation. Furthermore, we found that mutant ETV6 protein oligomerizes with WT ETV6 and sequesters it from the nucleus suggesting a dominant negative mechanism.
    [Show full text]
  • (NGS) for Primary Endocrine Resistance in Breast Cancer Patients
    Int J Clin Exp Pathol 2018;11(11):5450-5458 www.ijcep.com /ISSN:1936-2625/IJCEP0084102 Original Article Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients Ruoyang Li1*, Tiantian Tang1*, Tianli Hui1, Zhenchuan Song1, Fugen Li2, Jingyu Li2, Jiajia Xu2 1Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 2Institute of Precision Medicine, 3D Medicines Inc., Shanghai, China. *Equal contributors. Received August 15, 2018; Accepted September 22, 2018; Epub November 1, 2018; Published November 15, 2018 Abstract: Multiple mechanisms have been detected to account for the acquired resistance to endocrine therapies in breast cancer. In this study we retrospectively studied the mechanism of primary endocrine resistance in estrogen receptor positive (ER+) breast cancer patients by next-generation sequencing (NGS). Tumor specimens and matched blood samples were obtained from 24 ER+ breast cancer patients. Fifteen of them displayed endocrine resistance, including recurrence and/or metastases within 24 months from the beginning of endocrine therapy, and 9 pa- tients remained sensitive to endocrine therapy for more than 5 years. Genomic DNA of tumor tissue was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks. Genomic DNA of normal tissue was extracted from peripheral blood mononuclear cells (PBMC). Sequencing libraries for each sample were prepared, followed by target capturing for 372 genes that are frequently rearranged in cancers. Massive parallel
    [Show full text]
  • ETV6/GOT1 Fusion in a Case of T(10;12)(Q24;P13)- Sis of Refractory Anemia with Excess Blasts (RAEB)
    Letters to the Editor bone marrow showed 10% blasts establishing the diagno- ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)- sis of refractory anemia with excess blasts (RAEB). Five positive myelodysplastic syndrome months later, she was admitted with a fever. A bone mar- row evaluation confirmed the transformation to an acute myeloid leukemia (AML) M1 according to the FAB classi- The ETV6/GOT1 fusion, resulting from t(10;12) fication. The patient died five days later. (q24;p13), has been recently described in a myelo- At diagnosis, karyotype revealed 46,XX,del(5)(q13q34) dysplastic syndrome. We reported a second case of [11]/46,idem,t(10;12)(q24;p13)[5]/46,XX[6]. The cytoge- t(10;12)-positive myelodysplastic syndrome in netic analysis at transformation displayed:46,XX,der whom fluorescent in situ hybridization confirmed (2)t(2;11)(q34;q14~21),del(5)(q13q34),idic(8)(p12),t(10;12) the non-random translocation but molecular biol- (q24;p13)[22]. ogy analyses revealed a ETV6/GOT1 chimera vary- As this case was very similar to the one previously ing from the first case described. described,6 we tested the hypothesis of a fusion involving ETV6 and GOT1 genes. Hybridization with the Citation: Struski S, Mauvieux L, Gervais C, Hélias C, Liu KL, and Lessard M. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome. Haematologica ETV6/AML1 probe (Abbott), which covers the SAM 2008 Mar; 93(3):467-468. doi: 10.3324/haematol.11988 domain of ETV6, and BAC RP11-441O15 (RZPD, Berlin, Germany) for the GOT1 locus, confirmed fusion signals of ETV6 (ets variant gene 6) is frequently rearranged in ETV6 and GOT1 on both derivative chromosomes 12 and both myeloid and lymphoid hematologic malignancies and 10 (Figure 1A).
    [Show full text]
  • ETS Fusion Genes in Prostate Cancer
    D Gasi Tandefelt et al. ETS fusion genes in prostate 21:3 R143–R152 Review cancer ETS fusion genes in prostate cancer Correspondence 1 2 1 1 Delila Gasi Tandefelt , Joost Boormans , Karin Hermans and Jan Trapman should be addressed to D Gasi Tandefelt Departments of 1Pathology and 2Urology, Erasmus University Medical Centre, PO Box 2040, 2000 CA Rotterdam, Email The Netherlands [email protected] Abstract Prostate cancer is very common in elderly men in developed countries. Unravelling the Key Words molecular and biological processes that contribute to tumor development and progressive " prostate cancer growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and " gene fusion TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene " androgen regulation that encodes a member of the family of ETS transcription factors. At lower frequency, other " ETS gene members of this gene family are also rearranged and overexpressed in prostate cancer. " prostate specific TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate. " translocation Most of the less frequent ETS fusion partners are also androgen-regulated and prostate- specific. During the last few years, novel concepts of the process of gene fusion have emerged, and initial experimental results explaining the function of the ETS genes ERG and ETV1 in prostate cancer have been published. In this review, we focus on the most relevant ETS gene fusions and summarize the current knowledge of the role of ETS transcription factors in prostate cancer. Finally, we discuss the clinical relevance of TMRPSS2–ERG and other ETS gene fusions in prostate cancer.
    [Show full text]
  • ETV6 Gene ETS Variant 6
    ETV6 gene ETS variant 6 Normal Function The ETV6 gene provides instructions for producing a protein that functions as a transcription factor, which means that it attaches (binds) to specific regions of DNA and controls the activity of certain genes. The ETV6 protein is found in the nucleus of cells throughout the body, where it turns off (represses) gene activity. It plays a key role in development before birth and in regulating blood cell formation. Health Conditions Related to Genetic Changes PDGFRB-associated chronic eosinophilic leukemia PDGFRB-associated chronic eosinophilic leukemia, a type of cancer of blood-forming cells, can be caused by a genetic rearrangement known as a translocation that brings together part of the ETV6 gene and part of another gene called PDGFRB, creating the ETV6-PDGFRB fusion gene. The translocation that leads to the ETV6-PDGFRB fusion gene is a somatic mutation, which is acquired during a person's lifetime and occurs initially in a single cell. This cell continues to grow and divide, producing a group of cells with the same mutation (a clonal population). The protein produced from the ETV6-PDGFRB fusion gene, called ETV6/PDGFRb , functions differently than the proteins normally produced from the individual genes. Unlike the normal PDGFRb protein, the fusion protein is always active, which means certain cell signaling pathways are constantly turned on. The fusion protein is unable to repress gene activity regulated by the normal ETV6 protein, so gene activity is increased. The overactive signaling pathways and abnormal gene activity increase the proliferation and survival of cells. When the ETV6-PDGFRB fusion gene mutation occurs in cells that develop into blood cells, the growth of white blood cells called eosinophils (and occasionally other white blood cells, such as neutrophils and mast cells) is poorly controlled, leading to PDGFRB-associated chronic eosinophilic leukemia.
    [Show full text]
  • Data Integration for Identification of Important Transcription Factors of STAT6-Mediated Cell Fate Decisions
    Data integration for identification of important transcription factors of STAT6-mediated cell fate decisions M. Jargosch1*, S. Kröger2*, E. Gralinska1, U. Klotz1,3, Z. Fang1, W. Chen4, U. Leser2, J. Selbig3, D. Groth3 and R. Baumgrass1 1Signal Transduction, German Rheumatism Research Center (DRFZ), Berlin, Germany 2Knowledge Management in Bioinformatics, Humboldt-Universität zu Berlin, Berlin, Germany 3Bioinformatics Group, University of Potsdam, Potsdam, Germany 4Scientific Genomics Platform, Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany *These authors contributed equally to this study. Corresponding author: R. Baumgrass E-mail: [email protected] Genet. Mol. Res. 15 (2): gmr.15028493 Received January 26, 2016 Accepted March 17, 2016 Published June 24, 2016 DOI http://dx.doi.org/10.4238/gmr.15028493 ABSTRACT. Data integration has become a useful strategy for uncovering new insights into complex biological networks. We studied whether this approach can help to delineate the signal transducer and activator of transcription 6 (STAT6)-mediated transcriptional network driving T helper (Th) 2 cell fate decisions. To this end, we performed an integrative analysis of publicly available RNA-seq data of Stat6- knockout mouse studies together with STAT6 ChIP-seq data and our own gene expression time series data during Th2 cell differentiation. We focused on transcription factors (TFs), cytokines, and cytokine receptors and delineated 59 positively and 41 negatively STAT6-regulated genes, Genetics and Molecular Research 15 (2): gmr.15028493 ©FUNPEC-RP www.funpecrp.com.br M. Jargosch et al. 2 which were used to construct a transcriptional network around STAT6. The network illustrates that important and well-known TFs for Th2 cell differentiation are positively regulated by STAT6 and act either as activators for Th2 cells (e.g., Gata3, Atf3, Satb1, Nfil3, Maf, and Pparg) or as suppressors for other Th cell subpopulations such as Th1 (e.g., Ar), Th17 (e.g., Etv6), or iTreg (e.g., Stat3 and Hif1a) cells.
    [Show full text]